News about Global Pharma

CHMP Recommends T-DXd EU Approval in HER2-Low/Ultralow Breast Cancer

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

Global Pharma | 04/03/2025 | By Aishwarya |  309

IDEAYA Biosciences Teams Up with ATTMOS to Tackle Undruggable Oncology Targets

IDEAYA Biosciences, Inc. announced a research collaboration with ATTMOS as part of its efforts to build a physics-based computational small molecule discovery platform that rapidly unlocks what are currently perceived as undruggable oncology targets.

Global Pharma | 03/03/2025 | By Manvi |  180

Glenmark Pharmaceuticals Acquires and Launches Acetylcysteine Injection in US

Glenmark Pharmaceuticals Inc., USA, has acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA Inc and launched it in the US market.

Global Pharma | 03/03/2025 | By Manvi |  478

Renovaro and BioSymetrics to Boost AI-Driven Biomarker Discovery and Precision Medicine

At the core of this collaboration is BioSymetrics’ proprietary Elion platform, a cutting-edge AI and machine learning engine that uncovers complex biological relationships to accelerate the discovery of diagnostics and therapeutics.

Global Pharma | 03/03/2025 | By Aishwarya |  290

Akums Signs MoU with NIFTEM-T to Strengthen Industry-Academia Partnership

Under this agreement, NIFTEM-T students will be provided with internship opportunities at Akums, allowing them to gain hands-on industry experience.

Global Pharma | 03/03/2025 | By Aishwarya |  478

Fapon Biopharma Receives FDA Approval of IND for FP008 for Solid Tumors

FP008 is a novel anti-PD-1×IL-10M fusion protein with a unique mechanism of action (MOA) and therapeutic potential for anti-PD-1 naïve or resistant patients.

Global Pharma | 03/03/2025 | By Aishwarya |  374

Arrowhead Pharmaceuticals Expands its New Patient-Centric Resources for FCS Patients

This new phase introduces a dedicated educational website, and the Spotlight on FCS white paper, which provides essential resources and support for those affected by Familial Chylomicronemia Syndrome (FCS).

Global Pharma | 03/03/2025 | By Aishwarya |  251

Magnet Biomedicine and Lilly to Develop Novel Molecular Glue Medicines

The collaboration will leverage Magnet's TrueGlue™ discovery platform to identify molecular glues capable of inducing protein proximity and cooperativity, enabling novel mechanisms of action to address difficult-to-drug targets spanning multiple diseases with unmet medical need.

Global Pharma | 01/03/2025 | By Aishwarya |  672

Foresight Diagnostics Expands Strategic Partnership with Allogene Therapeutics

Under the strategic collaboration, Allogene and Foresight will work together to support the development of Foresight Diagnostics' MRD assay in the EU, UK, Canada and Australia in support of Allogene's clinical development of cema-cel.

Global Pharma | 01/03/2025 | By Manvi |  245

Nxera Pharma and Holling to Commercialize Daridorexant in Taiwan

Daridorexant is an oral dual orexin receptor antagonist (DORA) for the treatment of insomnia that selectively binds to receptors of the wake-promoting neuropeptide orexin (OX1R and OX2R), inhibiting excessive wakefulness and facilitating the transition to sleep.

Global Pharma | 01/03/2025 | By Aishwarya |  461